These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11695314)

  • 1. [New perspectives in the treatment of viral hepatitis C: pegylated interferon alpha].
    Alric L; Cacoub P
    Rev Med Interne; 2001 Oct; 22(10):922-5. PubMed ID: 11695314
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.
    Thompson AJ; Muir AJ; Sulkowski MS; Patel K; Tillmann HL; Clark PJ; Naggie S; Fellay J; Ge D; McCarthy JJ; Goldstein DB; McHutchison JG
    Hepatology; 2010 Dec; 52(6):2243-4. PubMed ID: 20890887
    [No Abstract]   [Full Text] [Related]  

  • 3. Second thoughts about secondary analyses.
    Ferenci P
    Dig Liver Dis; 2005 Oct; 37(10):805-7; author reply 808-9. PubMed ID: 16023903
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to issues raised in the Jansen/Reesink editorial.
    Silva M
    J Hepatol; 2007 Feb; 46(2):350-1. PubMed ID: 17161883
    [No Abstract]   [Full Text] [Related]  

  • 6. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha.
    Sherman M; Marinos G; Sedarati F
    Ann Intern Med; 2001 Nov; 135(10):927-8. PubMed ID: 11712887
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality of life with pegylated interferon therapy for hepatitis C.
    Brown RS
    Hepatology; 2002 Sep; 36(3):767-8; author reply 768. PubMed ID: 12198677
    [No Abstract]   [Full Text] [Related]  

  • 8. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):246-8. PubMed ID: 24366456
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimal dosage of ribavirin.
    Mangia A; Andriulli A
    Hepatology; 2010 Sep; 52(3):1174. PubMed ID: 20812365
    [No Abstract]   [Full Text] [Related]  

  • 10. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.
    Teta D; Lüscher BL; Gonvers JJ; Francioli P; Phan O; Burnier M
    Nephrol Dial Transplant; 2005 May; 20(5):991-3. PubMed ID: 15741205
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-acting interferon: studies on pegylated interferon].
    Ma H; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):78-9. PubMed ID: 11856520
    [No Abstract]   [Full Text] [Related]  

  • 12. Cure of acute hepatitis C in HIV co-infection?
    Ristig MB; Tebas P; Gandy I; Qaqish R; Aberg JA
    J Clin Gastroenterol; 2004 Mar; 38(3):303. PubMed ID: 15128087
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.
    Venezia G; Licata A; Di Marco V; Craxì A; Almasio PL
    Dig Liver Dis; 2005 Nov; 37(11):882-5. PubMed ID: 16169301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon and ribavirin in real life: efficacy versus effectiveness.
    de Mattos AZ; de Almeida PR; Tovo CV; de Mattos AA
    Hepatology; 2010 Nov; 52(5):1867. PubMed ID: 20726033
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of hepatitic C virus infection after the French 2002 Consensus Conference].
    Cacoub P
    Rev Med Interne; 2002 Nov; 23(11):889-92. PubMed ID: 12481388
    [No Abstract]   [Full Text] [Related]  

  • 16. Two consecutive episodes of acute hepatitis C with different genotypes in a hemodialysis patient responsive to PEG-interferon monotherapy.
    Lederer S; Zachoval R; Hasholzner U; Schiffl H
    Clin Nephrol; 2008 Apr; 69(4):313-6. PubMed ID: 18397710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Healing hepatitis C infections. Pegylated interferon alfa-2a opens new perspectives].
    MMW Fortschr Med; 2003 Jun; 145(26):52-3. PubMed ID: 12916339
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 19. [Systemic lupus erythematosus syndrome induced by interferon therapy].
    Martínez Alfaro E; Mateos Rodríguez F; Blanch Sancho JJ; Tárraga Rodríguez I
    Med Clin (Barc); 2004 Oct; 123(15):597. PubMed ID: 15535949
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.
    Dimova RB; Talal AH
    J Hepatol; 2010 Sep; 53(3):418-20. PubMed ID: 20561707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.